Population pharmacokinetics of raxibacumab in healthy adult subjects

Oosterholt, Sean; Pasqua, Oscar Della

doi:10.1111/bcp.14894

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previously developed population pharmacokinetic model in adult healthy subjects was used as the basis for the extrapolation of the disposition properties of raxibacumab in the paediatric population 16 (companion paper). Despite the lack of specific data for this class of antibodies, stochastic parameter distributions have been assumed to be comparable across populations (i.e.…”

Section: Methodsmentioning

confidence: 99%

Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years

Oosterholt

Pasqua

2021

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

What is already known about this subjecto Raxibacumab is recommended for administration in adult patients as a single intravenous dose of 40 mg/kg, with paediatric doses ranging from 40 mg/kg to 80 mg/kg. These doses have been selected under the assumption that drug disposition across the overall paediatric population varies primarily due to developmental growth What this study addso This study assesses whether maturation processes in neonates, infants, and toddlers, affect raxibacumab disposition and consequently the systemic exposure in this group of patients.o While mAb pharmacokinetics are known to vary due to body weight, dosing regimens in paediatrics need to consider maturation processes to ensure optimized exposure.

show abstract

Section: Methodsmentioning

confidence: 99%

Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years

Oosterholt

Pasqua

2021

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?

et al. 2022

View full text Add to dashboard Cite

Although COVID-19 has captured most of the public health attention, antimicrobial resistance (AMR) has not disappeared. To prevent the escape of resistant microorganisms in animals or environmental reservoirs a “one health approach” is desirable. In this context of COVID-19, AMR has probably been affected by the inappropriate or over-use of antibiotics. The increased use of antimicrobials and biocides for disinfection may have enhanced the prevalence of AMR. Antibiotics have been used empirically in patients with COVID-19 to avoid or prevent bacterial coinfection or superinfections. On the other hand, the measures to prevent the transmission of COVID-19 could have reduced the risk of the emergence of multidrug-resistant microorganisms. Since we do not currently have a sterilizing vaccine against SARS-CoV-2, the virus may still multiply in the organism and new mutations may occur. As a consequence, there is a risk of the appearance of new variants. Nature-derived anti-infective agents, such as antibodies and antimicrobial peptides (AMPs), are very promising in the fight against infectious diseases, because they are less likely to develop resistance, even though further investigation is still required.

show abstract

Population pharmacokinetics of raxibacumab in healthy adult subjects

Cited by 2 publications

References 19 publications

Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years

Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years

Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?

Contact Info

Product

Resources

About